OpenLoop alternatives

Tessic Health is the best OpenLoop alternative in 2026: a flat $25 per completed consult, 0% medication markup, no revenue share, and month-to-month terms, with the patients, the records, and the revenue staying with the brand. OpenLoop's written proposal, set out line by line on the Tessic Health vs OpenLoop comparison page, quotes $9,000 implementation, $1,500 a month from the first patient seen, a 12-month initial term, and retention of 50 to 59 percent of what a maintenance patient pays, as of September 4, 2026. Beluga Health, Telegra, Wheel, CareValidate, Fuse Health, and Remedora are the other alternatives. The decision turns on what a platform publishes, who holds the money, and how much of the clinic arrives operated.

The search usually starts with the remittance schedule rather than the software. In OpenLoop's own proposal, a maintenance tirzepatide patient pays $339 a month, the brand receives $138, and OpenLoop retains $201, about 59 percent, for as long as that patient stays. That share also grows with tenure, from roughly 42 percent in month one, so the hardest asset a brand builds accrues to the platform.

The second reason is structural. Patients are charged into OpenLoop's merchant account, OpenLoop holds the card tokens and billing records, and the brand is paid weekly on OpenLoop's own count of active patients, so leaving means re-collecting authorization from every patient. Add a 12-month term and a January 7, 2026 breach affecting up to 716,000 patients across client brands, confirmed on the HHS Office for Civil Rights breach portal.

Beluga Health is the closest alternative on clinical shape: physician-founded, LegitScript certified, and built on an async intake and review workflow tuned for high-volume consumer flows, with licensed providers across all 50 states and fulfillment through partner pharmacies. That certification is also a commercial unlock, since it gates Google and Meta advertising for prescription telehealth.

The trade is transparency and scope. Beluga publishes no rate card, no per-consult fee, and no medication markup, quoting deals individually as of September 4, 2026, so margin stays unknown until late in a sales cycle. Its public scope centers on visits and fulfillment rather than the billing, retention, and analytics included in Tessic Health's plans.

Wheel is the enterprise answer to the same problem. Founded in 2018 in Austin, it reports more than $216 million raised, 7 million patient visits, and 70 or more care programs on its Wheel Horizon platform, with a clinician network governed by Wheel Medical Group and fulfillment through Amazon Pharmacy.

For a founder-led brand the fit is poor for one reason: nothing is published. Wheel lists no per-consult fee, no subscription rate, and no medication markup, so unit economics arrive only after a procurement cycle, and its TPA offering targets go-live in under 90 days. Tessic Health's Scale plan covers the same multi-brand territory on published terms: $4,000 a month after a $25,000 setup, with unlimited brands on one account.

Fuse Health is purpose-built for compounded peptides: intake, formularies, and follow-up workflows structured for that vertical, licensed providers in all 50 states, async review, routing to accredited compounding pharmacies, and either a pre-built branded storefront or a medical API.

The fee structure is what to model. Its published pricing lists monthly tiers of $299, $699, and $3,000, a merchant service fee on every sale of 10 percent on the entry tier and 2 percent above it, and per-consult fees of $20 async and $35 sync, as of September 4, 2026. That is a percentage of revenue that grows with the brand, the same objection that sends operators looking for an alternative.

There is a real buyer for whom OpenLoop is the right answer, and it is not the cash-pay founder. If the program bills payers rather than patients, OpenLoop's network of more than 600 plans, per its site, is infrastructure no platform here matches, Tessic Health included, since Tessic is built for cash-pay brands. If a health system is embedding virtual care through APIs and an EHR-ready deployment across 35 or more specialties, that breadth is genuine. If procurement demands NCQA-certified credentialing by name, OpenLoop publishes it and most alternatives do not.

Scale is a fair argument too: OpenLoop reports more than 400 brands and 700,000 patients a month, and its Launchpad tool builds a storefront in as little as 24 hours. The boundary is this. If the program is payer-billed, integration-heavy, or credential-gated, stay and negotiate. If it is cash-pay and the model is subscription retention, the remittance schedule is the cost.